Neuroprotective poly-guanidino compounds which block presynaptic N and P/Q calcium channels

US6063819A · kind A · utility

Assignee

• Cypros Pharmaceutical Corp. · US

Inventors

• Paul J. Marangos · Encinitas, US
• Brian Sullivan · Escondido, US
• Torsten Wiemann · Encinitas, US
• Anne M. Danks · Solana Beach, US
• Marina Sragovicz · San Diego, US
• Lewis R. Makings · Encinitas, US

Key dates

• Filing date: Feb 18, 1998
• Grant date: May 16, 2000
• Expiry date: Feb 18, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/165
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Neuroprotective drugs are disclosed with at least 3 branches extending outwardly from a center atom or group, each branch having a guanidino group at its terminus. All branches preferably should be identical, and distributed around the center atom or group in a radial manner. Three branches can be bonded to a nitrogen atom, or four branches can be coupled to a carbon atom; other center groups include stable aromatic, cycloalkyl, heterocyclic, or bicyclic structures. Starting reagents are disclosed with a center atom or group, and with reactive groups (such as primary amines or hydroxyl groups) at the ends of short "spacer chains" bonded to the center atom or group. Reagents derived from arginine (an amino acid having a terminal guanidino group) can be bonded to these center components, using protective groups on the arginyl reagents to ensure desired final products with accessible guanidino groups at the ends of spacer chains. Alternately, guanylating agents can be used to directly convert primary amine groups at the ends of spacer chains, on starting reagents, into guanidino groups. These drugs can be injected intravenously into patients suffering from ischemic or hypoxic crises (…